Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Engert

Showing results (231-240 of 379) with videos related to

Pageof 38
Sort By:
International Journal of Radiation Oncology, Biology, Physics|August 21, 2007
A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG)Hans Theodor Eich, Axel Gossmann, Andreas Engert, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 9, 2018
Metabolic Tumour Volume for Response Prediction in Advanced-Stage Hodgkin LymphomaJasmin Mettler, Horst Müller, Conrad-Amadeus Voltin, et al.
Clinical Trials (London, England)|May 8, 2016
Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial settingAjay K Gopal, Barbara Pro, Joseph M Connors, et al.
The Lancet. Oncology|October 14, 2011
Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trialThomas Elter, Liana Gercheva-Kyuchukova, Halyna Pylylpenko, et al.
European Journal of Haematology|March 22, 2005
Imaging of central nervous system lymphomas with iodine-123 labeled rituximabMarkus Dietlein, Hendrik Pels, Holger Schulz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 6, 2013
Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patientsKatrin S Reiners, Jörg Kessler, Maike Sauer, et al.
Haematologica|August 26, 2003
Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomasPeter Borchmann, Franck Morschhauser, Anne Parry, et al.
Leukemia & Lymphoma|February 14, 2013
Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphomaStephanie Sasse, Achim Rothe, Helen Goergen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2005
Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibodyRoland Schnell, Markus Dietlein, Jan Oliver Staak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2017
Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 TrialsPaul J Bröckelmann, Helen Goergen, Charlotte Kohnhorst, et al.
Pageof 38

Showing results (231-240 of 379) with videos related to

Sort By:
Pageof 38
International Journal of Radiation Oncology, Biology, Physics|August 21, 2007
A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG)Hans Theodor Eich, Axel Gossmann, Andreas Engert, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 9, 2018
Metabolic Tumour Volume for Response Prediction in Advanced-Stage Hodgkin LymphomaJasmin Mettler, Horst Müller, Conrad-Amadeus Voltin, et al.
Clinical Trials (London, England)|May 8, 2016
Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial settingAjay K Gopal, Barbara Pro, Joseph M Connors, et al.
The Lancet. Oncology|October 14, 2011
Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trialThomas Elter, Liana Gercheva-Kyuchukova, Halyna Pylylpenko, et al.
European Journal of Haematology|March 22, 2005
Imaging of central nervous system lymphomas with iodine-123 labeled rituximabMarkus Dietlein, Hendrik Pels, Holger Schulz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 6, 2013
Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patientsKatrin S Reiners, Jörg Kessler, Maike Sauer, et al.
Haematologica|August 26, 2003
Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomasPeter Borchmann, Franck Morschhauser, Anne Parry, et al.
Leukemia & Lymphoma|February 14, 2013
Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphomaStephanie Sasse, Achim Rothe, Helen Goergen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2005
Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibodyRoland Schnell, Markus Dietlein, Jan Oliver Staak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2017
Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 TrialsPaul J Bröckelmann, Helen Goergen, Charlotte Kohnhorst, et al.
Pageof 38